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3014Objective: The present study assessed the effectiveness of preoperative transcatheter occlusion of the broncho-
pulmonary collateral artery (PTOBPCA) in reducing reperfusion pulmonary edema after pulmonary thromboen-
darterectomy (PEA).
Methods: The data from 155 patients with chronic thromboembolic pulmonary hypertension at Anzhen Hospi-
tal, treated from January 2007 to August 2013, with PEAwere retrospectively reviewed. The patients were clas-
sified into a control (group A, n ¼ 87) and treated (group B, underwent PTOBPCA, n ¼ 68) group. The
reperfusion pulmonary edema incidence, mechanical ventilation and intensive care unit hospitalization duration,
and hemodynamic function were compared between the 2 groups.
Results:Of the 87 patients in group A, 5 died in-hospital (5.7%mortality); no patient in group B died (0%mor-
tality; P¼ .035). In group A, 9 patients (10.3%) required extracorporeal membrane oxygenation (ECMO) after
PEA; 1 patient (1.5%) in group B required ECMO (chi-square test, P¼ .026, c2¼ 4.980). Group B had shorter
intubation and intensive care unit hospitalization times, lower mean pulmonary artery pressures and pulmonary
vascular resistance, higher partial pressures of oxygen in arterial blood and oxygen saturation, and decreased
medical expenditure compared with group A. During a mean 37.1  21.4 months of follow-up, 3 patients
in group A and 2 in group B died; however, the difference in the actuarial survival at 3 years postoperatively
between the 2 groups was not statistically significant.
Conclusions: PTOBPCA can reduce the incidence of reperfusion pulmonary edema, shorten intensive care unit
hospitalization and intubation duration, improve early hemodynamic function, and reduce ECMO usage after
PEA. (J Thorac Cardiovasc Surg 2014;148:3014-9)Chronic thromboembolic pulmonary hypertension
(CTEPH) is a progressive disease characterized by chronic
thromboemboli accumulation within the pulmonary ar-
teries, leading to severe pulmonary hypertension. Pulmo-
nary thromboendarterectomy (PEA) of the major, lobar,
and segmental pulmonary arteries is the primary therapy
for affected patients and can be curative in select patients.
PEA has emerged as the treatment of choice for CTEPH1;
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The Journal of Thoracic and Cardiovascular Surmajor risk factor and complication during and immediately
after PEA and has been associated with adverse short-term
and long-term consequences.2 The in-hospital mortality has
been as high as 15% after PEA in some reports, with the
principal causes being RPE and persistent pulmonary
hypertension.3
Bronchopulmonary arterial dilatation is a well-
recognized feature in patients with CTEPH.4 In our
practice, we have found that the patients undergoing preop-
erative transcatheter occlusion of the bronchopulmonary
collateral artery (BPCA) tended to have a more uneventful
recovery than those who had not undergone the procedure.
Therefore, we hypothesized that preoperative transcatheter
occlusion of the BPCA (PTOBPCA) might reduce the inci-
dence of RPE and improve early hemodynamic function
after PEA. To test this hypothesis, we retrospectively eval-
uated patients with CTEPH who had undergone PTOBPCA
and those who had not and measured the rate of postopera-
tive complications, such as RPE, mechanical ventilation
duration, morbidity, and mortality.METHODS
The local ethics committee at Beijing Anzhen Hospital and Beijing
Institute of Heart, Lung, and Blood Vessel Diseases approved the use ofgery c December 2014
Abbreviations and Acronyms
BPCA ¼ bronchopulmonary collateral artery
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
ECMO ¼ extracorporeal membrane oxygenation
ICU ¼ intensive care unit
OPS ¼ occluded pulmonary segment
PEA ¼ pulmonary thromboendarterectomy
RPE ¼ reperfusion pulmonary edema
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informed consent to undergo the surgical or transcatheter procedure and
the use of their data for clinical research.
Patients
A total of 155 consecutive PEA procedures performed on patients diag-
nosed with CTEPH at the Beijing Anzhen Hospital, China, from January
2007 to August 2013, were evaluated. Patient age at the initial admission
ranged from 17 to 75 years (mean, 45.7  16.2). Of the 155 patients, 78
were categorized into World Health Organization functional class IV and
79 into World Health Organization functional class III. Additionally, 93
patients had a history of deep vein thrombosis in the lower extremities.
Preoperatively, the enlarged BPCAs were not occluded in 87 patients
(group A) and were occluded in 68 patients (group B).
Pulmonary angiography, pulmonary artery computed tomographic
angiography or pulmonary artery magnetic resonance imaging, isotope
ventilation/perfusion scintigraphy, and echocardiography were used to
characterize the pathophysiologic features of CTEPH and to calculate
the occluded pulmonary segment (OPS). In 95% of the patients, pulmonary
artery computed tomographic angiography and isotope ventilation/perfu-
sion scintigraphy were performed within 7 days before PEA.
Right-sided heart catheterization was performed preoperatively to
assess the hemodynamic status in all 155 patients. The right atrial pressure,
pulmonary artery pressure, and pulmonary capillary wedge pressure were
measured using standard clinical methods, and the cardiac output was
measured using the Fick procedure. Additionally, the patients underwent
right-sided heart catheterization 0 and 72 hours after PEA using a Swan-
Ganz catheter while hospitalized in the intensive care unit (ICU).
From the imaging findings, physical examination results, and pathologic
assessment of the CTEPH surgical specimen, 113 patients were classified
as having the proximal type and 42 as having the distal type of CTEPH. The
patient demographics and risk factors for both groups are summarized in
Table 1. The CTEPH lesion classification, pulmonary vascular resistance,
pulmonary to systemic systolic artery pressure ratio, mean pulmonary ar-
tery pressure, partial pressure of oxygen in arterial blood, and oxygen satu-
ration were distributed equally between the 2 groups.
A total of 216 patients received a surgical consultation, and 155 under-
went surgical therapy. The patients were selected for PTOBPCA if they had
a history of, or ongoing, hemoptysis symptoms.
Therapeutic Regimen
At 3 to 7 days before undergoing PEA, group B underwent transcatheter
occlusion of the enlarged BPCA during the preoperative right-sided heart
catheterizations, with the patient under local anesthesia. The normal bron-
chial artery and enlarged BPCAwere identified using thoracic aortography,
subclavian arteriography, and selective bronchopulmonary arteriography.
The normal bronchial arteries were left untreated, and the enlarged
BPCA (diameter  1.5 mm) and the associated bronchopulmonary collat-
eral vasculature were occluded by transcatheter coil placement. Complete
vascular occlusion of the target vessel was assessed using angiography atThe Journal of Thoracic and Carprocedure completion. Embolization of the enlarged BPCAwas uneventful
in all 68 patients. A mean of 1.9 0.7 BPCAs were occluded using a mean
of 2.6  1.2 coils.
All 155 patients with CTEPH underwent standard PEA under general
anesthesia with cardiopulmonary bypass and deep hypothermia circulatory
arrest. PEAwas performed through a median sternotomy, similar to tech-
niques established by Jamieson and Kapelanski.5 The mean cardiopulmo-
nary bypass duration was 232.6  35.2 minutes, the mean clamping
duration was 93.2 23.2 minutes, and the mean circulatory arrest duration
was 35.7  12.6 minutes.
All surviving patients in both groups received lifelong warfarin postop-
eratively, and the international normalized ratio was maintained within a
range of 2.0 to 3.0. Select patients with residual pulmonary hypertension
received pulmonary vasodilator therapy, including prostanoids, endothelin
receptor antagonists, phosphodiesterase-5 inhibitors, or a combination of
therapies.
Follow-up
Valid and complete follow-up information was obtained for 148 of the
150 surgical survivors (98.7%) every 3 months and yearly. The World
Health Organization functional class and 6-minute walk test, transthoracic
echocardiography, electrocardiography, chest radiography, and pulmonary
artery computed tomographic angiography findings were recorded. The
long-term clinical outcome was assessed through July 2013.
Statistical Analysis
All statistical analyses were performed using the Statistical Package for
Social Sciences, version 17.0 (SPSS, Inc, Chicago, Ill). Summary statistics
for all continuous variables are presented as the mean standard deviation.
Categorical data were summarized as frequencies and percentages. Cumu-
lative event rates, such as actuarial survival, were estimated using the
Kaplan-Meier method. Differences between the 2 groups were analyzed us-
ing the chi-square test, Fisher’s exact test, t test, or log-rank test, as
appropriate.RESULTS
Early Outcomes
The classification and frequency of graded RPE are listed
in Table 2. Of the 87 patients in group A, 9 (10.3%) had the
most severe form, grade 5 RPE, and required life-sustaining
extracorporeal membrane oxygenation (ECMO) therapy.
Of the 68 patients in group B, 1 (1.5%) had grade 5 RPE
and also required life-sustaining ECMO therapy (chi-square
test, P ¼ .026, c2 ¼ 4.980).
During the early postoperative period, 5 patients in group
A died in-hospital (5.75%). None of the 68 patients in group
Bdied (0%; Fisher’s exact test,P¼ .068). The 5 early deaths
in group Awere attributed to grade 5 RPE, with or without
persistent pulmonary artery hypertension and right-side
heart failure (Table 3). The 2 groups were also compared
by intubation and ICU duration, mean pulmonary artery
pressure, pulmonary vascular resistance, partial pressure
of oxygen in arterial blood, oxygen saturation, and medical
expenditure. The findings are summarized in Table 4.Long-Term Outcomes
The 150 surgical survivors were followed up for 1 to 80
months (mean, 37.1  21.4). The cumulative follow-updiovascular Surgery c Volume 148, Number 6 3015








Male gender (n) 54 (62.1) 39 (57.4) .668 (0.184)
Age (y) 46.7  13.5 47.8  12.8 .607 (0.515)
Disease course (y) 3.6  2.8 3.7  2.5 .818 (0.231)
WHO functional class .785 (0.074)
III 43 (49.4) 36 (52.9)
IV 44 (50.6) 32 (47.1)
PaO2 (mm Hg) on room air 66.3  8.4 64.3  6.3 .104 (1.636)
SaO2 (%) on room air 87.2  3.7 86.3  3.8 .140 (1.485)
PaO2/FiO2 ratio 262  38 270  32 .166 (1.392)
sPAP (mm Hg) 96.8  26.4 93.5  22.5 .412 (0.823)
PVR (dynes/s/cm5) 878  426 851  381 .682 (0.410)
sPAP  100 mm Hg (%) 45 (51.7) 36 (52.9) .880 (0.023)
sPAP/sBP ratio 0.86  0.16 0.89  0.14 .223 (1.223)
mPAP (mm Hg) 68.4  12.7 67.7  13.5 .741 (0.331)
Ventilation/perfusion scan
(defect segment, OPS)
12.7  2.8 12.1  2.5 .168 (1.387)
CTEPH classification .736 (0.114)
Proximal type 62 51
Distal type 25 17
Data presented as n (%) or mean  standard deviation.WHO, World Health Organi-
zation; PaO2, partial pressure of oxygen in arterial blood; SaO2, oxygen saturation;
PaO2/FiO2 ratio, ratio of arterial oxygen tension to fraction of inspired oxygen;
sPAP, systolic pulmonary artery pressure; PVR, pulmonary vascular resistance;
sPAP/sBP, pulmonary to systemic systolic artery pressure ratio; mPAP, mean pulmo-
nary artery pressure; OPS, occluded pulmonary segment; CTEPH, chronic thrombo-
embolic pulmonary hypertension.
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tients in group A died, at 11 months, 4 years, and 5 years
postoperatively, of persistent pulmonary artery hyperten-
sion and right-sided heart failure. Two patients in group B
died 3 and 6 years after the procedure. From the Kaplan-
Meier actuarial survival analysis, the difference in actuarial
survival at 3 years postoperatively between groups A and B
was not statistically significant (92.9%  2.8% vs 97.2%
 2.7%, log-rank test, c2 ¼ 2.189, P ¼ .139). The ventila-
tion/perfusion scintigraphy studies performed 3 months af-
ter PEA showed that the OPS had decreased from 12.7 2.8
preoperatively to 2.6 0.7 defect segments postoperatively
in the 82 group A survivors (t¼ 31.738, P¼ .000). In the 68
group B survivors, the ventilation/perfusion scintigraphy
studies revealed that the OPS had decreased from 12.1 
2.5 preoperatively to 2.7  0.9 defect segments postopera-
tively (t¼ 28.981, P¼ .000). However, the difference in re-
sidual OPS between the 2 groups was not statistically
significant (t ¼ 0.763, P ¼ .447).
DISCUSSION
Although PEA has been the treatment of choice for
CTEPH and has the potential to cure the disease,6 it has re-
mained a rare or uncommon procedure, mainly because
postoperative RPE has often led to severe mortality and
morbidity. The PEA mortality has ranged from 5% to3016 The Journal of Thoracic and Cardiovascular Sur8.7% at experienced medical centers7,8 and has been as
great as 10% to 20% at less experienced centers,9 with
RPE the single most implicated cause.
RPE will occur in 10% to 60% of patients, depending on
the clinical definition,10,11 and patients can experience
deteriorated oxygenation and carbon dioxide clearance
despite high levels of inspiratory oxygen, high peak
inspiratory pressures, and high positive end-expiratory
pressures. RPE is a high permeability edema occurring in
endarterectomized and reperfused regions.12 At its most se-
vere, RPE can cause severe alveolar hemorrhage, with pro-
found hypoxemia and high mortality.13 Although the
incidence of this syndrome has gradually decreased, poten-
tially 3% to 6% of patients with severe cases will require
temporary support with ECMO according to a recent
series.14
Post-PEA RPE can have a highly variable presentation,
from minor radiopacities on the chest radiograph to the
most severe form requiring life-sustaining ECMO.15 To
date, no practical grading or reporting system is available
for post-PEA RPE. In a study of percutaneous transluminal
pulmonary angioplasty by Inami and colleagues,16 RPEwas
graded into 5 groups according to the severity; however, the
RPE that develops after PEA has been far more severe than
the lesions that have developed after percutaneous translu-
minal pulmonary angioplasty. Therefore, their grading sys-
tem is not directly applicable to the present study. Instead,
this RPE grading system was revised into a new formulation
(Table 2). Of the 155 patients in the present series, 133
(85.8%) were considered to have grades 2 to 4, clearly indi-
cating RPE occurrence, and 10 (6.45%) were considered to
have grade 5, the most severe form of RPE, and required
ECMO and/or extended ventilatory support (>7 days).
The exact cause and pathogenesis of RPE, whether sec-
ondary to the thromboendarterectomy itself, as suggested
by Levinson and colleagues,12 or to reperfusion injury of
the ischemic pulmonary endothelium,17 remains under
investigation. In previous studies of isolated lungs and ani-
mal models, postischemia reperfusion was associated with
increased microvascular lung permeability18 and pulmo-
nary sequestration of activated polymorphonuclear neutro-
phils.19 Similarly, Fadel and colleagues20 surmised that
the acute high-permeability pulmonary edema that develops
after thromboendarterectomy results from an acute inflam-
matory response to the ischemia and reperfusion. In contrast
to Levinson and colleagues,12 Fadel and colleagues20 re-
ported that it is neither induced nor aggravated by the
thromboendarterectomy itself. The pulmonary arterial in-
tima might be disrupted during endarterectomy, leading to
surgical endothelial injury, activation of the complement,
coagulation, and kinin systems, and concomitant changes
in endothelial permeability.12,21 Lung reperfusion is
followed by a dramatic transient increase in endothelial
cell apoptosis, which might trigger endothelialgery c December 2014
TABLE 2. Classification and frequency of graded RPE in surgical CTEPH patients
Grade RPE definition Group A (n ¼ 87) Group B (n ¼ 68)
1 No significant recognition of RPE on chest radiograph, ventilation without
needing PEEP to maintain arterial saturation at optimum level, and
extubated within 24 h after procedure
6 16
2 Mild or small RPE on chest radiograph, ventilation needing PEEP to
maintain arterial saturation at optimum level, and extubated within 72 h
after procedure
28 18
3 Moderate RPE on chest radiograph, ventilation needing PEEP to maintain
arterial saturation at optimum level, and extubated within 120 h after
procedure
26 26
4 Severe RPE on chest radiograph, ventilation needing PEEP to maintain
arterial saturation at optimum level, and extubated within 148 h after
procedure
16 7
5 Extremely severe RPE on chest radiograph such that artificial ventilation
and PEEP cannot maintain arterial saturation at optimum level, and
ECMO should be installed during or after the procedure, or the ventilation
duration exceeded 148 h and tracheotomy performed
9 1
Data presented as number of patients. P ¼ .005 (c2 ¼ 14.9). RPE, Reperfusion pulmonary edema; PEEP, positive end-expiratory pressure; ECMO, extracorporeal membrane
oxygenation.
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reperfusion induced apoptosis in>30% of parenchymal
lung cells in human patients and animal models after
lung transplantation.22 Thus, increased apoptosis might
contribute substantially to the development of RPE and
persistent pulmonary hypertension. Antiapoptotic agents
could hold considerable potential for preventing postopera-
tive complications.23
BPCAs develop in patients with CTEPH to perfuse the
patent vasculature distal to the embolic obstruction.24 Luxu-
riant perfusion in these vessel structures after PEA could be
associated with RPE.12 Potentially, the large blood volume
redirected to previously occluded pulmonary capillary beds
postoperatively could be the catalyst for this reperfusion
phenomenon after pulmonary endarterectomy.25
Treatment of RPE has primarily been supportive. In most
cases, therapy comprising mechanical ventilation, diuretics,
and avoidance of hypercarbia and supranormal inspired ox-
ygen concentrations will allow full lung recovery.26 Most
patients will respond well to these aggressive measures.27
Several strategies have been attempted to reduce the inci-
dence of RPE. Mares and colleagues28 proved in a clinical
trial that avoiding positive inotropic catecholamines and va-
sodilators and using nonaggressive mechanical ventilation
(low tidal volume and low peak inspiratory pressure) were
associated with a low incidence of RPE and right-side heart
failure after PEA. In the more severe cases, neutrophil adhe-
sion inhibitors, high-dose corticosteroids,29 inhaled nitric
oxide,30 and aerosolized iloprost31 have been administered
to limit RPE, with varying success. However, a very small
number of PEA patients will develop life-threatening RPE
postoperatively despite a good initial hemodynamic
outcome. For such patients, ECMOmight be the only effec-
tive therapy.14,27 In the present case series, 10 patientsThe Journal of Thoracic and Car(6.45%) with grade 5 RPE had difficulty weaning from
extracorporeal circulation and were immediately
implanted with ECMO devices to allow survival.
We have surmised that the BPCAmight be among the pri-
mary triggers for RPE after PEA. Pulmonary arterial ob-
structions with thromboembolic pulmonary hypertension
are patchy and will largely spare the small pulmonary ar-
teries and arterioles.32 This will allows a pressure gradient
to develop between the systemic bronchial circulation and
the pulmonary circulation distal to the proximal pulmonary
arterial obstruction, encouraging BPCA growth. Subse-
quently, all patients with thromboembolic pulmonary
hypertension also had dilated bronchial arteries and
numerous bronchopulmonary collaterals. The BPCAs
serve the pulmonary arterial branches downstream of the
occluded site. Endrys and colleagues4 reported that all pa-
tients with CTEPH had significant BPCA blood flow,
approximately 30% of the systemic blood flow. It has
been speculated that alleviating disease in the small subseg-
mental pulmonary vessels, rather than themain or lobar ves-
sels, might, in some patients, trigger a vascular leak-like
syndrome that causes a severe reperfusion response. This
response might reflect increased flow through new small
areas of open vessels that leads to a significant ventila-
tion–perfusion mismatch.33
After the embolized pulmonary arteries have been
opened by endarterectomy, the affected lung will experi-
ence dual arterial perfusion, which will overwhelm its endo-
thelial endurance, increase permeability, and, ultimately,
trigger RPE. PTOBPCA avoids this dual arterial perfusion
insult after PEA, preventing or alleviating the occurrence
of RPE. We were intrigued by this practice and have adop-
ted PTOBPCA in select PEA procedures, especially in pa-
tients with symptoms or a history of hemoptysis. Duringdiovascular Surgery c Volume 148, Number 6 3017




Early death (before postoperative discharge)
1 7 d A Grade 5 RPE, persistent
pulmonary hypertension,
and right-sided heart failure
2 15 d A Grade 5 RPE, persistent
pulmonary hypertension,
and right-sided heart failure
3 5 d A Grade 5 RPE
4 8 d A Grade 5 RPE, persistent
pulmonary hypertension,
and right-sided heart failure
5 9 d A Grade 5 RPE
Late death (after postoperative discharge)
6 11 mo A Persistent pulmonary
hypertension and
right-sided heart failure
7 3 y B Copious hemoptysis
8 4 y A Persistent pulmonary
hypertension and
right-sided heart failure
9 5 y A Persistent pulmonary
hypertension and
right-sided heart failure
10 6 y B Persistent pulmonary
hypertension and
right-sided heart failure
Pt. no., Patient number; RPE, reperfusion pulmonary edema.
TABLE 4. Comparison between groups A and B for intubation time,








Intubation (h) 71.7  27.5 39.8  15.6 .000 (8.547)
ICU stay (d) 4.8  2.9 3.5  2.6 .004 (2.897)
mPAP (mm Hg)
At 0 h 38.6  10.4 33.2  9.1 .001 (3.386)
At 72 h 35.5  11.9 28.4  10.2 .000 (3.921)
PVR (dynes/s/cm5)
At 0 h 456.3  182 362  176 .002 (3.248)
At 72 h 342  213 256  143 .005 (2.862)
PaO2 (mm Hg) at 72 h 88.1  16.7 105.2  22.1 .000 (5.423)
PaO2/FiO2 ratio at 72 h 379  42 428  36 .000 (7.667)
Medical expenditure (10
thousand RMB)
18.6  3.9 15.5  3.4 .000 (5.191)
Data presented as mean  standard deviation. ICU, Intensive care unit; mPAP, mean
pulmonary artery pressure; PVR, pulmonary vascular resistance; PaO2, partial pres-
sure of oxygen in arterial blood; PaO2/FiO2 ratio, ratio of arterial oxygen tension
to fraction of inspired oxygen; 0 h, immediately postoperatively; 72 h, 72 h postop-
eratively; RMB, renminbi.
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touched, eliminating any risk of new pulmonary infarctions
after BPCA embolization. Thus, no patients developed new
hemoptysis symptoms after PTOBPCA in our series. This is
the first report describing PTOBPCA before PEA. We
believe it is worthwhile to compare the PEA procedures
with and without the PTOBPCA strategy.
Bronchopulmonary arterial rupture can cause severe and
sometimes lethal hemoptysis. Reesink and colleagues34 re-
ported that 5 of 79 patients with CTEPH (6%) in a case se-
ries had had moderate to severe hemoptysis requiring
medical intervention. Because most patients with CTEPH
will require lifelong anticoagulant therapy, a therapeutic
dilemma can ensue. Therefore, Reesink and colleagues34
proposed that even mild hemoptysis in patients with
CTEPH warrants prompt evaluation, and embolization
treatment should be offered as the first choice for these pa-
tients. Accordingly, in the present study, PTOBPCA was
initially performed in patients with CTEPH and mild to se-
vere hemoptysis beginning in January 2007. The patients
undergoing BPCA occlusion had a much more uneventful
surgical recovery than did those who had not undergone
the procedure. Therefore, the procedure was performed in
more patients, primarily those with a history of hemoptysis.
PTOBPCA continued to be conducive to post-PEA3018 The Journal of Thoracic and Cardiovascular Surrecovery. Therefore, the present retrospective study was
initiated to document its effect. The analysis has confirmed
that PTOBPCA reduces ECMO usage, alleviates REP, and
improves early hemodynamics after PEA.
The difference in the preoperative and postoperative OPS
between the 2 groups did not reach statistical significance;
therefore, the difference in postoperative performance
cannot be attributed to the different thromboendarterectomy
technique but instead to PTOBPCA. The patients undergo-
ing PTOBPCA were less likely to require ECMO, had
decreased intubation times, shorter ICU stays, lower mean
pulmonary artery pressures and pulmonary vascular resis-
tance, and higher oxygen saturation and partial pressures
of oxygen in arterial blood after PEA (Table 2). Overall,
PTOBPCA appears to effectively prevent RPE after PEA
and could provide several distinct advantages.
Study Limitations
The present study had several limitations. This was a
retrospective, single-center study performed during a
6-year period and lacked randomization. Thus, any clear as-
sociation between the early and late PEA and PTOBPCA
outcomes are obscured. To definitively assess the efficacy
of PTOBPCA, additional studies of a larger population
are needed to confirm the present findings. Overall, the sam-
ple size was limited and other risk factors could not be
controlled; therefore, the present study results should be
considered inconclusive and preliminary. A randomized
controlled trial is needed to determine the role of
PTOBPCA in preventing RPE.
CONCLUSIONS
PTOBPCA can alleviate RPE, shorten the ICU stay,
decrease the intubation duration, reduce ECMO usage,gery c December 2014
Gan et al Acquired Cardiovascular Diseaseand improve early hemodynamic function after PEA.
Should additional clinical investigations confirm that
PTOBPCA improves the PEA outcome, wider implementa-
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